A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
12/5/2025
BreakingCataractDealsDry EyeFLACSGlaucomaIOLPharmaSurgical
Bausch + Lomb Outlines Growth Plans, Driven by Deep Pipeline
Bausch + Lomb used its investor day on Nov. 13 to lay out how it plans to produce growth of 6 to 8 percent in its surgical segment and 5 to 7 percent in its pharmaceutical, consumer, and contact le...
12/5/2025
BreakingDealsDry Eye
Iolyx Licenses Autoimmune Dry Eye Candidate to Théa in Deal Worth Up to $280 Million
Iolyx Therapeutics announced Dec. 3 that it had granted rights worldwide, excluding Asia, to France’s Laboratoires Théa to develop and commercialize ILYX-002, an immune-modulating eye drop candidat...
12/5/2025
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Drops to Rxilient for Countries in Southeast Asia
Taiwan-based Formosa Pharmaceuticals announced Dec. 3 that it had agreed to license to Rxilient Medical exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammatio...
12/5/2025
BreakingPharmaRegulation
CDER Chief Pazdur Retiring from US FDA; Makary Names Høeg as Replacement
Oncologist Richard Pazdur, MD, is reportedly retiring from his role as the US FDA’s director of the Center for Drug Evaluation and Research (CDER) after less than a month in the job. The FDA announ...
12/5/2025
BreakingIndustryRetina
Clearside to Pursue Strategic Sale Through Chapter 11 Process
Clearside Biomedical announced Nov. 24 that it had filed for Chapter 11 bankruptcy protection and intended to pursue an auction and sale of its business. Clearside, of Alpharetta, Georgia, had repo...
12/5/2025
BreakingDealsGlaucomaPharmaRegulation
Ocuvex Resubmits NDA to US FDA for Once-Daily Brimonidine Drop
India’s Sun Pharma Advanced Research Company (SPARC) announced Nov. 20 that its partner Ocuvex had resubmitted the new drug application to the US FDA for PDP-716, a once-daily eye drop formulation ...
12/5/2025
BreakingIndustry
RVL Pharmaceuticals, Maker of Upneeq, Appoints Lori Deo as CEO
RVL Pharmaceuticals, of Bridgewater, New Jersey, announced Nov. 24 that it had appointed Lori Deo as chief executive officer. Deo had served as executive chairwoman of the board prior to the appoin...
12/5/2025
BreakingIndustryRetina
Visara Appoints Cadmus Rich, MD, MBA, as Chief Medical Officer
NovaBridge Biosciences announced Nov. 20 that its ophthalmic subsidiary, Visara, had appointed ophthalmologist Cadmus Rich, MD, MBA, as its chief medical officer (CMO). Visara acquired VIS-101, for...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.